Zyus Life Sciences Corporation · TSXV:ZYUS
Zyus Life Sciences — Investor Presentation (October 2026)
26 slides from Zyus Life Sciences's investor presentation, Oct 9, 2026
Slide 1: Advancing Non-Opioid Solutions
ZYUS’ ADVANCING NON-OPIOID SOLUTIONS Clinical-stage biotechnology company developing proprietary, multi- mechanism therapies for pain management FOR CHRONIC & NEUROPATHIC PAIN TSW) 3 ANUS October 2026 v2.3.7
Slide 2: Cautionary Statement
Caut nary Statement This document is current as of October 9, 2026 except where otherwise stated. The information contained in this presentation is provided by ZYUS Life Sciences Corporation ("ZYUS" or the “Company’) for informational purposes only and does not constitute an offer to issue or arrang
Slide 3: Transforming Pain Management: Vision
Transforming — Pain Management — VISION 4 To transform the treatment of chronic a “ neuropathic pain by advancing a clinical-stage pipeline of novel, non-opioid therapies leveraging polypharmacology to deliver safer alternatives to conventional pain medications.
Slide 4: Building a Differentiated Non-Opioid Pain Platform
Wal’ AUS $$ Building a Differentiated Advancing proprietary non-opioid therapies across multiple high-need Non-Opioid Pain Platform pammpetistions, DIFFERENTIATED MULTI-MECHANISM = CLINICAL-STAGE DRUG PIPELINE APPROACH PIPELINE Proprietary non-opioid Developed to target Positive topline results cand
Slide 5: Crisis Meets Opportunity
UNMET Nb) ——— 03 Crisis Meets Opportunity ° 50M+ 1in5 17M+ U.S. adults living BshecTe) 61) ko U.S. adults living with chronic pain. experience chronic with high-impact £ pain. chronic pain. ‘ Market Size The Treatment Gap The Opioid Challenge USD $72B+ — $115B+ A significant unmet need @ Globallchra
Slide 6: A Significant Gap in Pain Management
THE TREATMENT GAP A Significant Gap in Pain Management THE TREATMENT GAP Opioids Moderate to Severe Pain ay NsaiDs Ss) Mild to Moderate Pain Trichomylin® Commonly used for mild Eagle pais to moderate pain Investigational non-opioid drug candidate Highly effective analgesics Widely used and accessibl
Slide 7: A Significant Gap in Data-Driven Drug Development for Pain Management
INTEGRATING REAL-WORLD EVIDENCE A Significant Gap in Data-Driven Drug Development for Pain Management 05 Patient-Reported Uses of Cannabinoid-Based Products We move beyond anecdotal insights to substantiate our understanding of patient experiences. oO 58% Pain Management Neurological Disorders Fi ‘
Slide 8: Two Patented, Complementary Non-Opioid Candidates
PIPELINE 06 Advancing a differentiated pain Two Patented, Complementary Non- _ | piatormwith the potential to Opioid Candidates LEAD DRUG CANDIDATE Trichomylin® Softgel Capsules A proprietary, fixed-dose, multi-mechanism oral therapy. Targets Peripheral and Central Pain Pathways Including voltage-ga
Slide 9: Polypharmacology Designed to Fill the Gap
IMIE(CIRVAINTISIM] OlP ANCL) 07 Polypharmacology Designed to Fill the Gap Voltage-Gated ‘ Ce . : r Transient Receptor Sodium Channels Pale : “J ———— Potential (TRP) lon {NaVs) .° Q/\c, ne q h : a Inhibits Nav1.8 - the same gs validated target class F . annels and infla mat ory . ‘underlying recently
Slide 10: Non-Opioid Pain Relief Through NaV Channel Inhibitors
NEW CLASS OF PAIN MEDICATION Non-Opioid Pain Relief Through NaV Channel Inhibitors Trichomylin® Softgel Capsules ¢ The cannabinoids in Trichomylin® softgel capsules, particularly cannabidiol, exhibit mechanisms similar to Vertex’s Suzetrigine (VX-548) by inhibiting voltage-dependent sodium channels
Slide 11: Trichomylin Demonstrated Analgesic Activity in Preclinical Models
DRUG DISCOVERY Trichomylin® Demonstrated Analgesic Activity in Preclinical Models Marked Reduction of Mechanical Hyperalgesia (A) The Effect of Treatment on Mechanical Hyperalgesia Evaluated at (B) Area Under The Curve (Mean + SEM) Baseline and Four Timepoints of 2h, 4h, 8h, and 24h Post-Treatment p
Slide 12: Phase 1 First-in-Human Results
CLINICAL DEVELOPMENT 10 Trichomylin® Softgel Capsules Phase 1 First-in-Human Results n=41 First-in-Human, randomized, double-blind, placebo-controlled, single and multiple ascending dose study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of Tricho
Slide 13: Phase 2a UTOPIA-1 Study Design Overview
PHASE 2a UTOPIA-1 Study Design Overview Single-arm, open-label, proof-of-concept study evaluating Trichomylin® softgel capsules in patients with advanced cancer and moderate to severe cancer-related pain. cancer experiencing moderate to severe cancer-related pain. ¢ On stable long-acting opioid ther
Slide 14: Feasibility of an Individualized Titration Dosing Regimen
PHASE 2a UTOPIA-1 | OBJECTIVE ONE Feasibility of an Individualized Titration Dosing Regimen @ Reached of patients 91% stable dose Did not reach stable dose (10 of 11) ¢ successfully titrated to an individualized stable dose level. e six patients reached the maximum dose allowable by the protocol. (n
Slide 15: Safety & Tolerability of Trichomylin Softgel Capsules
PHASE 2a UTOPIA-1 | OBJECTIVE TWO Safety & Tolerability of Trichomylin’ Softgel Capsules Y) Number of Participants with at Least 1 Treatment- al Related Treatment Emergent Adverse Event (TEAE): No treatment-related serious adverse events (SAEs) occurred, and four SAEs in one patient were assessed un
Slide 16: Pain Management Across Multiple Aspects of Pain
PHASE 2a UTOPIA-1 | OBJECTIVE THREE Pain Management Across Multiple Aspects of Pain In the subset of 7 evaluable patients that adhered to the treatment and assessment plan, pain analyses signaled a clinically relevant decrease in pain (a pre-defined >30% threshold for improvement) across multiple pa
Slide 17: Patient Impression of Change and Quality of Life
PHASE 2a UTOPIA-1 | OBJECTIVE FOUR Patient Impression of Change and Quality of Life Y Overall Positive signals in fatigue and insomnia were i 9, observed (EORTC QLQ-C30). The pre-defined Change in 14% threshold for clinically meaningful change in Health 29% condition of “Much Improved” was met in 29
Slide 18: Evaluation of Opioid Use
PHASE 2a UTOPIA-1 | OBJECTIVE FIVE Evaluation of Opioid Use Daily Average Rescue Opioid 7 oe Use by Phase: Individual Patients Percentage of Daily Rescue Opioid Use by Study Phase: 3 Patient ID Titration Stable Dose Discontinuation re) 7of7 sia Phase Phase Phase patients were prescribed rescue opioi
Slide 19: FDA Draft Guidance for Development of Non-Opioid Analgesics
REGULATORY LANDSCAPE FDA Draft Guidance for Development of Non-Opioid Analgesics for Chronic Pain iit = aa) Support Phase 3 Clinical Development Act Development Considerations Responds to the statutory FDA describes current Addresses trial design, requirements of the recommendations regarding patien
Slide 20: What Phase 2a UTOPIA-1 Supports
PHASE 2a UTOPIA-1 What Phase 2a UTOPIA-1 Supports Safety Short-term use of Trichomylin® softgel capsules was Titration 91% of patients (10/11) Study Design The Phase 2a UTOPIA-1 design generated practical Clinical Observation Phase 2a UTOPIA-1 trial results showed Trichomylin® softgel Future Directi
Slide 21: Conclusions and Implications
PHASE 2a UTOPIA-1 Conclusions and Implications Clinical Potential Trichomylin® softgel capsules may provide clinically meaningful additional pain management in a subset of opioid-treated patients with advanced cancer. O Patient Experience Trichomylin® softgel capsules may provide overall improvement
Slide 22: Drug Development Pipeline
PHASES OF DEVELOPMENT 20 Drug Development Pipeline THERAPEUTIC AREA Chronic Pain Management Neuropathic Pain @ cowetete DISCOVERY & COMPOUND NON-CLINICAL PHASE 1 PHASE 2a PHASE 2b STATUS PROGRAM Drug Product phase] Fa Candidate 1 Complete [richomylin® Vv Vv) v) » Oo 7 Positive topline Softgel Capsul
Slide 23: Building In-House Manufacturing Capacity
BUILDING IN-HOUSE MANUFACTURING CAPACITY 21 From Clinical Development to Scalable Commercial Production. Manufacturing Facility pile Purpose-built pharmaceutical fs manufacturing infrastructure designed to comply with cGMP standards. In-House Manufacturing R Capacity bag Supports formulation, produc
Slide 24: Robust Patent Portfolio
DISRUPIME ROUVENTIAL §$——— 22) Robust Patent Portfolio ¢ Trichomylin® Formulation Patent Protection © Overcoming Patent Challenges: Cannabinoids' long history of use and the fact that they are naturally occurring means patent protection is challenging to achieve. Despite these challenges, ZYUS succe
Slide 25: Governance and Advisory
DIRECTORS AND COMMITTEES Governance and Advisory Board of Directors Clinical Research Advisory Committee Richard Hoyt, Chair Dr. Lionel Marks de Chabris, Chair Brent Zettl Ms. Audrey Haukioja John Knowles Dr. Mary Lynch Garnette Weber Dr. Hance Clarke Wayne Brownlee, O.C. Dr. Alice Zwerling Dr. Char
Slide 26: Advancing the Science of Well-Being
ZYUS' ADVANCING THE SCIENCE OF WELL-BEING" TSXV : ZYUS
ZYUS Life Sciences — Investor Presentation (October 2026) on 6ix